Aspira Women's Health Inc. (AWHL) vs iSpecimen Inc. (ISPC)

Aspira Women's Health Inc. and iSpecimen Inc. are both Diagnostics & Research companies. iSpecimen Inc. is the larger, with a market value of $3.1M against $2.4M — 1.3× the size. Aspira Women's Health Inc. grew revenue faster over the last twelve months: −8.00% against −92.1%. Aspira Women's Health Inc. has the higher net margin (−117.1% vs −2,449.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Aspira Women's Health Inc. leads on 12 and iSpecimen Inc. on 4.

Valuation

Metric AWHL ISPC Diagnostics & Research median
P/E n/m n/m 33.95
P/S 1.35 3.77 4.87
P/B n/m 1.01 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m 0.31 25.20
EV/Sales 1.52 (5.55) 5.66
Earnings yield (93.85%) (4,479.37%) (1.75%)
Free cash flow yield (41.10%) (617.94%) (0.13%)

Profitability

Metric AWHL ISPC Diagnostics & Research median
Gross margin 58.78% (108.26%) 50.89%
Operating margin (80.75%) (2,020.05%) (8.57%)
Net margin (117.07%) (2,449.02%) (6.37%)
Free cash flow margin (55.32%) (1,866.61%) 0.00%
Return on equity 201.29% (968.44%) (2.92%)
Return on assets (213.58%) (170.09%) (6.71%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AWHL ISPC Diagnostics & Research median
Revenue growth (TTM) (8.00%) (92.11%) 7.69%
EPS growth (last fiscal year) 60.22% 87.03% —
Revenue growth, 5-year CAGR 14.66% (25.10%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AWHL ISPC Diagnostics & Research median
Debt to equity (0.27) 0.00 0.11
Current ratio 0.52 0.82 2.02
Net debt to EBITDA 0.00 0.95 0.78

Dividend

Metric AWHL ISPC Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AWHL ISPC Diagnostics & Research median
Market cap 2.44m 3.12m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack